Search - tctmd.com

Displaying 21 - 40 of 67

Sort: Relevancy | Date

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

L.A. McKeown

November 22, 2019

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Industry News

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

November 06, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Industry News

Intact Vascular Announces US Launch of the Tack Endovascular System® and First Commercial Use

May 07, 2019

News Industry News

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

April 16, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

Advertisement

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

FDA’s First Take on New Paclitaxel Concerns in CLI

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Intact Vascular Announces US Launch of the Tack Endovascular System® and First Commercial Use

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

TCTMD’s Top 10 Most Popular Stories for February 2019

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

5-Year Results from the IN.PACT SFA Randomized Trial

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content